Clinical Trial Results:
Tweede Immunisatie Men C (TIM)-studie
|
Summary
|
|
EudraCT number |
2011-000375-13 |
Trial protocol |
NL |
Global end of trial date |
19 Nov 2014
|
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 Oct 2026
|
First version publication date |
07 Oct 2026
|
Other versions |
|
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
|
Trial identification
|
|||
Sponsor protocol code |
LIS-144
|
||
|
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Other trial identifiers |
METC-nummer: R-11.09E/TIM , ABR-nummer: NL35207.100.11 , Clinical Trial Register Nummer: NTR 3521 | ||
|
Sponsors
|
|||
Sponsor organisation name |
RIVM
|
||
Sponsor organisation address |
PO Box 1, Bilthoven, Netherlands, 3720 BA
|
||
Public contact |
Clinical Expertise Centre, RIVM, mensgebonden-onderzoek@rivm.nl
|
||
Scientific contact |
Clinical Expertise Centre, RIVM, mensgebonden-onderzoek@rivm.nl
|
||
|
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
|
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
27 May 2015
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
19 Nov 2014
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
19 Nov 2014
|
||
Was the trial ended prematurely? |
No
|
||
|
General information about the trial
|
|||
Main objective of the trial |
To determine the appropriate age for a second immunization with the Meningococcal C conjugated vaccine.
|
||
Protection of trial subjects |
During this study the subjects will receive one dose of NeisVac-C™(Registration number: RVG 26343). NeisVac-C™ is a registered vaccine and currently used in the Dutch NIP for all children aged 14 months. Furthermore, the vaccine has already been used in the Netherlands (and other countries) in the same age group (children 10, 12 and 15 years of age) during the catch-up campaign in 2002. During the catch-up campaign over 3 million children were vaccinated and only 1512 developed an adverse reaction. It is therefore unlikely that serious side effects will occur that can lead to premature termination of the study.
The invasive study procedures (vaccination and venapunctures) will be carried out by experienced and qualified persons according to standard operating procedures. A local anesthetic (Xylocaine spray) can be used to minimize the pain of the venapuncture.
Furthermore, the burden and risk of blood and saliva sampling is considered low. Blood collection could result in a small bruise at the location of injection, which will disappear within a few days.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
02 May 2011
|
||
Long term follow-up planned |
Yes
|
||
Long term follow-up rationale |
Scientific research | ||
Long term follow-up duration |
3 Years | ||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
|
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Netherlands: 268
|
||
Worldwide total number of subjects |
268
|
||
EEA total number of subjects |
268
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
91
|
||
Adolescents (12-17 years) |
177
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
||
|
|||||||||||||||||||||||||||||||||||||||||
|
Recruitment
|
|||||||||||||||||||||||||||||||||||||||||
Recruitment details |
Persons of 10-15 years of age (year 1996-2002) who have previously received one MenCC vaccination and are living in or around Utrecht (Leidsche Rijn) (n=4500, 1500 per age group) were invited for participation in the study. Recruitment was done via an invitation letter to the parents. First inclusion: 3-Oct-2011. | ||||||||||||||||||||||||||||||||||||||||
|
Pre-assignment
|
|||||||||||||||||||||||||||||||||||||||||
Screening details |
Inclusion and exclusion was checked by the PI: inclusion -10-, 12, 15-years received primary vaccination MenCC; good general health; Received all regular vaccines of Dutch NIP exclusion: -acute illness; antibiotic use; serious disease, allergy to vaccin; immune deficiency; neurologic disorder; pregnancy; previous Meningococcal disease | ||||||||||||||||||||||||||||||||||||||||
|
Period 1
|
|||||||||||||||||||||||||||||||||||||||||
Period 1 title |
MenC immunization (overall period)
|
||||||||||||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||||||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||||||||||||||||||||
|
Arms
|
|||||||||||||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||||||||||||
|
Arm title
|
10 year olds | ||||||||||||||||||||||||||||||||||||||||
Arm description |
immune response to a second MenCC vaccination in age group 10 years old | ||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
NeisVac-C™
|
||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
RVG 26343
|
||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection in pre-filled syringe
|
||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use, Injection
|
||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
One dose of 0.5 ml for intramuscular injection contains 10 microgram of Neisseria meningitidis group C (strain C11) polysaccharide (de-O-acetylated). The polysaccharide is conjugated to 10-20 micrograms of tetanus toxoid and is adsorbed to aluminium hydroxide (0.5 mg). Other additive products are sodium chloride and water for injections.
The NeisVac-C™ vaccine (0.5 ml) is injected intramuscularly in the upper arm. This is a customary and well-accepted route of administration of this vaccine.
|
||||||||||||||||||||||||||||||||||||||||
|
Arm title
|
12 year olds | ||||||||||||||||||||||||||||||||||||||||
Arm description |
immune response to a second MenCC vaccination in age group 12 years old | ||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
NeisVac-C™
|
||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
RVG 26343
|
||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection in pre-filled syringe
|
||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use, Injection
|
||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
One dose of 0.5 ml for intramuscular injection contains 10 microgram of Neisseria meningitidis group C (strain C11) polysaccharide (de-O-acetylated). The polysaccharide is conjugated to 10-20 micrograms of tetanus toxoid and is adsorbed to aluminium hydroxide (0.5 mg). Other additive products are sodium chloride and water for injections.
The NeisVac-C™ vaccine (0.5 ml) is injected intramuscularly in the upper arm. This is a customary and well-accepted route of administration of this vaccine.
|
||||||||||||||||||||||||||||||||||||||||
|
Arm title
|
15 year olds | ||||||||||||||||||||||||||||||||||||||||
Arm description |
immune response to a second MenCC vaccination in age group 15 years old | ||||||||||||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product name |
NeisVac-C™
|
||||||||||||||||||||||||||||||||||||||||
Investigational medicinal product code |
RVG 26343
|
||||||||||||||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection in pre-filled syringe
|
||||||||||||||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use, Injection
|
||||||||||||||||||||||||||||||||||||||||
Dosage and administration details |
One dose of 0.5 ml for intramuscular injection contains 10 microgram of Neisseria meningitidis group C (strain C11) polysaccharide (de-O-acetylated). The polysaccharide is conjugated to 10-20 micrograms of tetanus toxoid and is adsorbed to aluminium hydroxide (0.5 mg). Other additive products are sodium chloride and water for injections.
The NeisVac-C™ vaccine (0.5 ml) is injected intramuscularly in the upper arm. This is a customary and well-accepted route of administration of this vaccine.
|
||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
10 year olds
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
immune response to a second MenCC vaccination in age group 10 years old | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
12 year olds
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
immune response to a second MenCC vaccination in age group 12 years old | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
15 year olds
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
immune response to a second MenCC vaccination in age group 15 years old | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||
|
End points reporting groups
|
|||
Reporting group title |
10 year olds
|
||
Reporting group description |
immune response to a second MenCC vaccination in age group 10 years old | ||
Reporting group title |
12 year olds
|
||
Reporting group description |
immune response to a second MenCC vaccination in age group 12 years old | ||
Reporting group title |
15 year olds
|
||
Reporting group description |
immune response to a second MenCC vaccination in age group 15 years old | ||
Subject analysis set title |
Age group 10 at T0
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Age group 10 T0
|
||
Subject analysis set title |
Age group 10 at T1
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Age group 10 T1
|
||
Subject analysis set title |
Age group 10 at T2
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Age group 10 at T2
|
||
Subject analysis set title |
Age group 12 at T0
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Age group 12 at T0
|
||
Subject analysis set title |
Age group 12 at T1
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Age group 12 at T1
|
||
Subject analysis set title |
Age group 12 at T2
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Age group 12 at T2
|
||
Subject analysis set title |
Age group 15 at T0
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Age group 15 at T0
|
||
Subject analysis set title |
Age group 15 at T1
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Age group 15 at T1
|
||
Subject analysis set title |
Age group 15 at T2
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Age group 15 at T2
|
||
Subject analysis set title |
Age group 10 at T3
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Age group 10 years old, sample T3
|
||
Subject analysis set title |
Age group 12 at T3
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Age group 12 years old , sample T3
|
||
Subject analysis set title |
Age group 15 at T3
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
Age group 15 years old, sample T3
|
||
|
|||||||||||||||||
End point title |
Geometric Mean Titers (GMTs) of MenC SBA levels at T0 | ||||||||||||||||
End point description |
Geometric Mean Titers (GMTs) of Meningococcal Serogroup C (MenC) Specific Serum Bactericidal Antibody (SBA) prior to (T0) the MenC Conjugate Booster.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
T0
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
GMT MenC SBA levels analysis 10 vs. 12 at T0 | ||||||||||||||||
Statistical analysis description |
Differences between groups in Serum Bactericidal Antibody (SBA) Geometric Mean Titers (GMTs) at T0 were determined using the Mann-Whitney U test. Differences between groups in SBA GMTs at T1 and T2 were determined with linear regression analyses, adjusting for titers at T0. P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
182
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.006 [1] | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [1] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMT MenC SBA levels analysis 10 vs. 15 at T0 | ||||||||||||||||
Statistical analysis description |
Differences between groups in Serum Bactericidal Antibody (SBA) Geometric Mean Titers (GMTs) at T0 were determined using the Mann-Whitney U test. Differences between groups in SBA GMTs at T1 and T2 were determined with linear regression analyses, adjusting for titers at T0.
|
||||||||||||||||
Comparison groups |
15 year olds v 10 year olds
|
||||||||||||||||
Number of subjects included in analysis |
177
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [2] | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [2] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMT MenC SBA levels analysis 12 vs. 15 at T0 | ||||||||||||||||
Statistical analysis description |
Differences between groups in Serum Bactericidal Antibody (SBA) Geometric Mean Titers (GMTs) at T0 were determined using the Mann-Whitney U test. Differences between groups in SBA GMTs at T1 and T2 were determined with linear regression analyses, adjusting for titers at T0.
|
||||||||||||||||
Comparison groups |
12 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
177
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.459 [3] | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [3] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Geometric Mean Titers (GMTs) of MenC SBA levels at T1 | ||||||||||||||||
End point description |
Geometric Mean Titers (GMTs) of Meningococcal Serogroup C (MenC) Specific Serum Bactericidal Antibody (SBA) 1 Month (T1) after the MenC Conjugate Booster.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
T1
|
||||||||||||||||
|
|||||||||||||||||
| Notes [4] - 1 insufficient blood sample |
|||||||||||||||||
Statistical analysis title |
GMT MenC SBA levels analysis 10 vs. 12 at T1 | ||||||||||||||||
Statistical analysis description |
Differences between groups in Serum Bactericidal Antibody (SBA) Geometric Mean Titers (GMTs) at T0 were determined using the Mann-Whitney U test. Differences between groups in SBA GMTs at T1 and T2 were determined with linear regression analyses, adjusting for titers at T0.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
177
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.021 [5] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [5] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMT MenC SBA levels analysis 10 vs. 15 at T1 | ||||||||||||||||
Statistical analysis description |
Differences between groups in Serum Bactericidal Antibody (SBA) Geometric Mean Titers (GMTs) at T0 were determined using the Mann-Whitney U test. Differences between groups in SBA GMTs at T1 and T2 were determined with linear regression analyses, adjusting for titers at T0.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
173
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.003 [6] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [6] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMT MenC SBA levels analysis 12 vs. 15 at T1 | ||||||||||||||||
Statistical analysis description |
Differences between groups in Serum Bactericidal Antibody (SBA) Geometric Mean Titers (GMTs) at T0 were determined using the Mann-Whitney U test. Differences between groups in SBA GMTs at T1 and T2 were determined with linear regression analyses, adjusting for titers at T0.
|
||||||||||||||||
Comparison groups |
12 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
174
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 1 [7] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [7] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Geometric Mean Titers (GMTs) of MenC SBA levels at T2 | ||||||||||||||||
End point description |
Geometric Mean Titers (GMTs) of Meningococcal Serogroup C (MenC) Specific Serum Bactericidal Antibody (SBA) 1 Year (T2) after the MenC Conjugate Booster.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
T2
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
GMT MenC SBA levels analysis 10 vs. 12 at T2 | ||||||||||||||||
Statistical analysis description |
Differences between groups in Serum Bactericidal Antibody (SBA) Geometric Mean Titers (GMTs) at T0 were determined using the Mann-Whitney U test. Differences between groups in SBA GMTs at T1 and T2 were determined with linear regression analyses, adjusting for titers at T0.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
174
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [8] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [8] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMT MenC SBA levels analysis 10 vs. 15 at T2 | ||||||||||||||||
Statistical analysis description |
Differences between groups in Serum Bactericidal Antibody (SBA) Geometric Mean Titers (GMTs) at T0 were determined using the Mann-Whitney U test. Differences between groups in SBA GMTs at T1 and T2 were determined with linear regression analyses, adjusting for titers at T0.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
168
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [9] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [9] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMT MenC SBA levels analysis 12 vs. 15 at T2 | ||||||||||||||||
Statistical analysis description |
Differences between groups in Serum Bactericidal Antibody (SBA) Geometric Mean Titers (GMTs) at T0 were determined using the Mann-Whitney U test. Differences between groups in SBA GMTs at T1 and T2 were determined with linear regression analyses, adjusting for titers at T0.
|
||||||||||||||||
Comparison groups |
12 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
172
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.021 [10] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [10] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Proportion of Participants with an SBA titer >=8 at T0 | ||||||||||||||||
End point description |
Percentage of Participants with an SBA titer >=8 prior to (T0) the MenC Conjugate Booster. Proportion and 95% confidence intervals (95%CIs) of participants with an SBA titer >=8 were calculated using the Agresti-Coull method.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
T0
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
SBA titer >=8 analysis 10 vs. 12 at T0 | ||||||||||||||||
Statistical analysis description |
An SBA titer >=8 was considered as international correlate of protection. Differences between groups in proportion of participants with an SBA titer >=8 was determined with Chi square test
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
182
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.057 [11] | ||||||||||||||||
Method |
Chi-squared | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [11] - P-values were adjusted for three comparisons with Bonferroni correction |
|||||||||||||||||
Statistical analysis title |
SBA titer >=8 analysis 10 vs. 15 at T0 | ||||||||||||||||
Statistical analysis description |
An SBA titer >=8 was considered as international correlate of protection. Differences between groups in proportion of participants with an SBA titer >=8 was determined with Chi square test
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
177
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [12] | ||||||||||||||||
Method |
Chi-squared | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [12] - P-values were adjusted for three comparisons with Bonferroni correction |
|||||||||||||||||
Statistical analysis title |
SBA titer >=8 analysis 12 vs. 15 at T0 | ||||||||||||||||
Statistical analysis description |
An SBA titer >=8 was considered as international correlate of protection. Differences between groups in proportion of participants with an SBA titer >=8 was determined with Chi square test
|
||||||||||||||||
Comparison groups |
12 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
177
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.375 [13] | ||||||||||||||||
Method |
Chi-squared | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [13] - P-values were adjusted for three comparisons with Bonferroni correction |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Proportion of Participants with an SBA titer >=8 at T1 | ||||||||||||||||
End point description |
Percentage of Participants with an SBA titer >=8 1 month (T1) after the MenC Conjugate Booster. Proportion and 95% confidence intervals (95%CIs) of participants with an SBA titer >=8 were calculated using the Agresti-Coull method.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
T1
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
SBA titer >=8 analysis 10 vs. 12 at T1 | ||||||||||||||||
Statistical analysis description |
An SBA titer >=8 was considered as international correlate of protection. Differences between groups in proportion of participants with an SBA titer >=8 was determined with Chi square test
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
178
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 1 [14] | ||||||||||||||||
Method |
Chi-squared | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [14] - P-values were adjusted for three comparisons with Bonferroni correction |
|||||||||||||||||
Statistical analysis title |
SBA titer >=8 analysis 10 vs. 15 at T1 | ||||||||||||||||
Statistical analysis description |
An SBA titer >=8 was considered as international correlate of protection. Differences between groups in proportion of participants with an SBA titer >=8 was determined with Chi square test
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
173
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 1 [15] | ||||||||||||||||
Method |
Chi-squared | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [15] - P-values were adjusted for three comparisons with Bonferroni correction |
|||||||||||||||||
Statistical analysis title |
SBA titer >=8 analysis 12 vs. 15 at T1 | ||||||||||||||||
Statistical analysis description |
An SBA titer >=8 was considered as international correlate of protection. Differences between groups in proportion of participants with an SBA titer >=8 was determined with Chi square test
|
||||||||||||||||
Comparison groups |
12 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
175
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 1 [16] | ||||||||||||||||
Method |
Chi-squared | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [16] - P-values were adjusted for three comparisons with Bonferroni correction |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Proportion of Participants with an SBA titer >=8 at T2 | ||||||||||||||||
End point description |
Percentage of Participants with an SBA titer >=8 1 year (T2) after the MenC Conjugate Booster. Proportion and 95% confidence intervals (95%CIs) of participants with an SBA titer >=8 were calculated using the Agresti-Coull method.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
T2
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
SBA titer >=8 analysis 10 vs. 12 at T2 | ||||||||||||||||
Statistical analysis description |
An SBA titer >=8 was considered as international correlate of protection. Differences between groups in proportion of participants with an SBA titer >=8 was determined with Chi square test
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
174
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 1 [17] | ||||||||||||||||
Method |
Chi-squared | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [17] - P-values were adjusted for three comparisons with Bonferroni correction |
|||||||||||||||||
Statistical analysis title |
SBA titer >=8 analysis 10 vs. 15 at T2 | ||||||||||||||||
Statistical analysis description |
An SBA titer >=8 was considered as international correlate of protection. Differences between groups in proportion of participants with an SBA titer >=8 was determined with Chi square test
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
168
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 1 [18] | ||||||||||||||||
Method |
Chi-squared | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [18] - P-values were adjusted for three comparisons with Bonferroni correction |
|||||||||||||||||
Statistical analysis title |
SBA titer >=8 analysis 12 vs. 15 at T2 | ||||||||||||||||
Statistical analysis description |
An SBA titer >=8 was considered as international correlate of protection. Differences between groups in proportion of participants with an SBA titer >=8 was determined with Chi square test
|
||||||||||||||||
Comparison groups |
12 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
172
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 1 [19] | ||||||||||||||||
Method |
Chi-squared | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [19] - P-values were adjusted for three comparisons with Bonferroni correction |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Geometric Mean Titers (GMTs) of MenC SBA levels at T3 | ||||||||||||||||
End point description |
Geometric Mean Titers (GMTs) of Meningococcal Serogroup C (MenC) Specific Serum Bactericidal Antibody (SBA) 3 years (T3) after the MenC Conjugate Booster vaccination.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
T3
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
GMT MenC SBA levels analysis 10 vs. 12 at T3 | ||||||||||||||||
Statistical analysis description |
Differences between groups in Serum Bactericidal Antibody (SBA) Geometric Mean Titers (GMTs) at T3 were determined with linear regression analyses, adjusting for titers at T0. P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
141
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [20] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [20] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMT MenC SBA levels analysis 10 vs. 15 at T3 | ||||||||||||||||
Statistical analysis description |
Differences between groups in Serum Bactericidal Antibody (SBA) Geometric Mean Titers (GMTs) at T3 were determined with linear regression analyses, adjusting for titers at T0. P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
124
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [21] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [21] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMT MenC SBA levels analysis 12 vs. 15 at T3 | ||||||||||||||||
Statistical analysis description |
Differences between groups in Serum Bactericidal Antibody (SBA) Geometric Mean Titers (GMTs) at T3 were determined with linear regression analyses, adjusting for titers at T0. P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
133
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.006 [22] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [22] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Proportion of Participants with an SBA titer >=8 at T3 | ||||||||||||||||
End point description |
Percentage of Participants with an SBA titer >8 3 years (T3) after the MenC Conjugate Booster. Proportions with 95% CI of participants
with an rSBA >=8 were calculated using the Wilson score interval with continuity correction.
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
T3
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Proportion GMT SBA >=8 10 vs. 12 at T3 | ||||||||||||||||
Statistical analysis description |
Differences in proportion of participants GMT SBA >-=8 at T3 were tested with the Chi-square test.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
141
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 1 | ||||||||||||||||
Method |
Chi-squared | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Proportion GMT SBA >=8 10 vs. 15 at T3 | ||||||||||||||||
Statistical analysis description |
Differences in proportion of participants GMT SBA >-=8 at T3 were tested with the Chi-square test.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
124
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 1 | ||||||||||||||||
Method |
Chi-squared | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Proportion GMT SBA >=8 12 vs. 15 at T3 | ||||||||||||||||
Statistical analysis description |
Differences in proportion of participants GMT SBA >-=8 at T3 were tested with the Chi-square test.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
133
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 1 | ||||||||||||||||
Method |
Chi-squared | ||||||||||||||||
Confidence interval |
|||||||||||||||||
|
|||||||||||||||||
End point title |
GMC MenC-PS specific IgG antibodies at T0 | ||||||||||||||||
End point description |
Geometric Mean Concentrations (GMCs) of Meningococcal Serogroup C Polysaccharide (MenC-PS) Specific Immunoglobulin G (IgG) prior to (T0) the MenC Conjugate Booster.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T0
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
GMC Men C IgG antibodies analysis 10 vs. 12 at T0 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG were determined with linear regression analyses, adjusting for concentrations at T0. GMC ratios indicate the level of increase (T1/T0) or decrease (T1/T2)
between time points. Differences in GMC ratios between groups were determined with independent sample t-tests.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
182
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.444 [23] | ||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [23] - linear regression analyses, adjusting for concentrations at T0. Differences in GMC ratios between groups were determined with independent sample t-tests. P-values were adjusted for three comparisons with Bonferroni correction |
|||||||||||||||||
Statistical analysis title |
GMC Men C IgG antibodies analysis 10 vs. 15 at T0 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG were determined with linear regression analyses, adjusting for concentrations at T0. GMC ratios indicate the level of increase (T1/T0) or decrease (T1/T2)
between time points. Differences in GMC ratios between groups were determined with independent sample t-tests.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
177
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.018 [24] | ||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [24] - linear regression analyses, adjusting for concentrations at T0. Differences in GMC ratios between groups were determined with independent sample t-tests. P-values were adjusted for three comparisons with Bonferroni correction |
|||||||||||||||||
Statistical analysis title |
GMC Men C IgG antibodies analysis 12 vs. 15 at T0 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG were determined with linear regression analyses, adjusting for concentrations at T0. GMC ratios indicate the level of increase (T1/T0) or decrease (T1/T2)
between time points. Differences in GMC ratios between groups were determined with independent sample t-tests.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
12 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
177
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.579 [25] | ||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [25] - linear regression analyses, adjusting for concentrations at T0. Differences in GMC ratios between groups were determined with independent sample t-tests. P-values were adjusted for three comparisons with Bonferroni correction |
|||||||||||||||||
|
|||||||||||||||||
End point title |
GMC MenC-PS specific IgG antibodies at T1 | ||||||||||||||||
End point description |
Geometric Mean Concentrations (GMCs) of Meningococcal Serogroup C Polysaccharide (MenC-PS) Specific Immunoglobulin G (IgG) 1 Month (T1) after the MenC Conjugate Booster.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T1
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
GMC Men C IgG antibodies analysis 10 vs. 12 at T1 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG were determined with linear regression analyses, adjusting for concentrations at T0. GMC ratios indicate the level of increase (T1/T0) or decrease (T1/T2)
between time points. Differences in GMC ratios between groups were determined with independent sample t-tests.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
178
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [26] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [26] - P-values were adjusted for three comparisons with Bonferroni correction |
|||||||||||||||||
Statistical analysis title |
GMC Men C IgG antibodies analysis 10 vs. 15 at T1 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG were determined with linear regression analyses, adjusting for concentrations at T0. GMC ratios indicate the level of increase (T1/T0) or decrease (T1/T2)
between time points. Differences in GMC ratios between groups were determined with independent sample t-tests.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
173
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.063 [27] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [27] - P-values were adjusted for three comparisons with Bonferroni correction |
|||||||||||||||||
Statistical analysis title |
GMC Men C IgG antibodies analysis 12 vs. 15 at T1 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG were determined with linear regression analyses, adjusting for concentrations at T0. GMC ratios indicate the level of increase (T1/T0) or decrease (T1/T2)
between time points. Differences in GMC ratios between groups were determined with independent sample t-tests.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
12 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
175
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 1 [28] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [28] - P-values were adjusted for three comparisons with Bonferroni correction |
|||||||||||||||||
|
|||||||||||||||||
End point title |
GMC MenC-PS specific IgG antibodies at T2 | ||||||||||||||||
End point description |
Geometric Mean Concentrations (GMCs) of Meningococcal Serogroup C Polysaccharide (MenC-PS) Specific Immunoglobulin G (IgG) 1 Year (T2) after the MenC Conjugate Booster.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T2
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
GMC Men C IgG antibodies analysis 10 vs. 12 at T2 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG were determined with linear regression analyses, adjusting for concentrations at T0. GMC ratios indicate the level of increase (T1/T0) or decrease (T1/T2)
between time points. Differences in GMC ratios between groups were determined with independent sample t-tests.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
174
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [29] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [29] - P-values were adjusted for three comparisons with Bonferroni correction |
|||||||||||||||||
Statistical analysis title |
GMC Men C IgG antibodies analysis 10 vs. 15 at T2 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG were determined with linear regression analyses, adjusting for concentrations at T0. GMC ratios indicate the level of increase (T1/T0) or decrease (T1/T2)
between time points. Differences in GMC ratios between groups were determined with independent sample t-tests.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
168
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [30] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [30] - P-values were adjusted for three comparisons with Bonferroni correction |
|||||||||||||||||
Statistical analysis title |
GMC Men C IgG antibodies analysis 12 vs. 15 at T2 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG were determined with linear regression analyses, adjusting for concentrations at T0. GMC ratios indicate the level of increase (T1/T0) or decrease (T1/T2)
between time points. Differences in GMC ratios between groups were determined with independent sample t-tests.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
12 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
172
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.033 [31] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [31] - P-values were adjusted for three comparisons with Bonferroni correction |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Men-C PS specific IgG memory B-cell responses at T0 | ||||||||||||||||
End point description |
Frequency of circulating MenC-PS-specific IgG memory B cells prior to (T0) the MenC conjugate booster vaccination. Geometric mean number of MenC-specific memory B cells per 100,000 B cells
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T0
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Men-C PS IgG memory B cells T0 10 vs. 12 years old | ||||||||||||||||
Statistical analysis description |
Mann-Whitney U test on circulating MenC-PS-specific memory B cells prior to (T0) the MenC conjugate booster vaccination. Geometric mean number of MenC-specific memory B cells per 100,000 B cells.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
30
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.7418 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Men-C PS IgG memory B cells T0 10 vs. 15 years old | ||||||||||||||||
Statistical analysis description |
Mann-Whitney U test on circulating MenC-PS-specific memory B cells prior to (T0) the MenC conjugate booster vaccination. Geometric mean number of MenC-specific memory B cells per 100,000 B cells.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
31
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.465 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Men-C PS IgG memory B cells T0 12 vs. 15 years old | ||||||||||||||||
Statistical analysis description |
Mann-Whitney U test on circulating MenC-PS-specific memory B cells prior to (T0) the MenC conjugate booster vaccination. Geometric mean number of MenC-specific memory B cells per 100,000 B cells.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
27
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.3933 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Men-C PS specific IgG memory B-cell responses at T1 | ||||||||||||||||
End point description |
Frequency of circulating MenC-PS-specific IgG memory B cells 1 month (T1) after the MenC conjugate booster vaccination. Geometric mean number of MenC-specific memory B cells per 100,000 B cells
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T1
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Men-C IgG memory B cells T1 10 vs. 12 years old | ||||||||||||||||
Statistical analysis description |
Frequency of circulating MenC-PS-specific memory B cells 1 month (T1) after the MenC conjugate booster vaccination. Geometric mean number of MenC-specific memory B cells per 100,000 B cells
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
33
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.0001 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Men-C IgG memory B cells T1 10 vs. 15 years old | ||||||||||||||||
Statistical analysis description |
Frequency of circulating MenC-PS-specific memory B cells 1 month (T1) after the MenC conjugate booster vaccination. Geometric mean number of MenC-specific memory B cells per 100,000 B cells
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
37
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.1131 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Men-C IgG memory B cells T1 12 vs. 15 years old | ||||||||||||||||
Statistical analysis description |
Frequency of circulating MenC-PS-specific memory B cells 1 month (T1) after the MenC conjugate booster vaccination. Geometric mean number of MenC-specific memory B cells per 100,000 B cells
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
32
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.0031 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Men-C PS specific IgG memory B-cell responses at T2 | ||||||||||||||||
End point description |
Frequency of circulating MenC-PS-specific IgG memory B cells 1 year (T2) after the MenC conjugate booster vaccination. Geometric mean number of MenC-specific memory B cells per 100,000 B cells
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T2
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Men-C PS IgG memory B cells T2 10 vs. 12 years old | ||||||||||||||||
Statistical analysis description |
Frequency of circulating MenC-PS-specific IgG memory B cells 1 year (T2) after the MenC conjugate booster vaccination. Geometric mean number of MenC-specific memory B cells per 100,000 B cells.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
31
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.0214 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Men-C PS IgG memory B cells T2 10 vs. 15 years old | ||||||||||||||||
Statistical analysis description |
Frequency of circulating MenC-PS-specific IgG memory B cells 1 year (T2) after the MenC conjugate booster vaccination. Geometric mean number of MenC-specific memory B cells per 100,000 B cells.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
35
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.1625 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Men-C PS IgG memory B cells T2 12 vs. 15 year old | ||||||||||||||||
Statistical analysis description |
Frequency of circulating MenC-PS-specific IgG memory B cells 1 year (T2) after the MenC conjugate booster vaccination. Geometric mean number of MenC-specific memory B cells per 100,000 B cells.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
32
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.4139 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
|
|||||||||||||||||
End point title |
GMC MenC-PS specific IgA in serum at T0 | ||||||||||||||||
End point description |
Geometric mean concentrations (GMCs) of MenC-polysaccharide specific IgA in serum prior to (T0) the MenC conjugate booster vaccination.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T0
|
||||||||||||||||
|
|||||||||||||||||
| Notes [32] - Only participants with sufficient amounts of saliva and serum available to perform all measurements. [33] - Only participants with sufficient amounts of saliva and serum available to perform all measurements. [34] - Only participants with sufficient amounts of saliva and serum available to perform all measurements. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgA in serum 10 vs. 12 at T0 | ||||||||||||||||
Statistical analysis description |
Comparisons of GMC MenC-PS specific IgA in serum at T0 between age groups were made using the Mann–Whitney U test. Comparisons between age groups at T1 and T2 were made using linear regression analyses with correction for values at T0. All p-values for these analyses were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
167
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.051 [35] | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [35] - All p-values for these analyses were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgA in serum 10 vs. 15 at T0 | ||||||||||||||||
Statistical analysis description |
Comparisons of GMC MenC-PS specific IgA in serum at T0 between age groups were made using the Mann–Whitney U test. Comparisons between age groups at T1 and T2 were made using linear regression analyses with correction for values at T0. All p-values for these analyses were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
156
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [36] | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [36] - All p-values for these analyses were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgA in serum 12 vs. 15 at T0 | ||||||||||||||||
Statistical analysis description |
Comparisons of GMC MenC-PS specific IgA in serum at T0 between age groups were made using the Mann–Whitney U test. Comparisons between age groups at T1 and T2 were made using linear regression analyses with correction for values at T0. All p-values for these analyses were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
161
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.21 [37] | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [37] - All p-values for these analyses were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
GMC MenC-PS specific IgA in serum at T1 | ||||||||||||||||
End point description |
Geometric mean concentrations (GMCs) of MenC-polysaccharide specific IgA in serum 1 month (T1) after the MenC conjugate booster vaccination.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T1
|
||||||||||||||||
|
|||||||||||||||||
| Notes [38] - Only participants with sufficient amounts of saliva and serum available to perform all measurements. [39] - Only participants with sufficient amounts of saliva and serum available to perform all measurements. [40] - Only participants with sufficient amounts of saliva and serum available to perform all measurements. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgA in serum 10 vs. 12 at T1 | ||||||||||||||||
Statistical analysis description |
Comparisons of GMC MenC-PS specific IgA in serum at T1 between age groups were made using linear regression analyses with correction for values at T0. All p-values for these analyses were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
169
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [41] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [41] - All p-values for these analyses were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgA in serum 10 vs. 15 at T1 | ||||||||||||||||
Statistical analysis description |
Comparisons of GMC MenC-PS specific IgA in serum at T1 between age groups were made using linear regression analyses with correction for values at T0. All p-values for these analyses were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
158
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [42] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [42] - All p-values for these analyses were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgA in serum 12 vs. 15 at T0 | ||||||||||||||||
Statistical analysis description |
Comparisons of GMC MenC-PS specific IgA in serum at T1 between age groups were made using linear regression analyses with correction for values at T0. All p-values for these analyses were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
161
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 1 [43] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [43] - All p-values for these analyses were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
GMC MenC-PS specific IgA in serum at T2 | ||||||||||||||||
End point description |
Geometric mean concentrations (GMCs) of MenC-polysaccharide specific IgA in serum 1 Year (T2) after the MenC conjugate booster vaccination.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T2
|
||||||||||||||||
|
|||||||||||||||||
| Notes [44] - Only participants with sufficient amounts of saliva and serum available to perform all measurements. [45] - Only participants with sufficient amounts of saliva and serum available to perform all measurements. [46] - Only participants with sufficient amounts of saliva and serum available to perform all measurements. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgA in serum 10 vs. 12 at T2 | ||||||||||||||||
Statistical analysis description |
Comparisons of GMC MenC-PS specific IgA in serum at T2 between age groups were made using linear regression analyses with correction for values at T0. All p-values for these analyses were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
169
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [47] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [47] - All p-values for these analyses were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgA in serum 10 vs. 15 at T2 | ||||||||||||||||
Statistical analysis description |
Comparisons of GMC MenC-PS specific IgA in serum at T2 between age groups were made using linear regression analyses with correction for values at T0. All p-values for these analyses were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
158
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [48] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [48] - All p-values for these analyses were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgA in serum 12 vs. 15 at T2 | ||||||||||||||||
Statistical analysis description |
Comparisons of GMC MenC-PS specific IgA in serum at T2 between age groups were made using linear regression analyses with correction for values at T0. All p-values for these analyses were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
161
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.174 [49] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [49] - All p-values for these analyses were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
GMC MenC-PS specific IgA in saliva at T0 | ||||||||||||||||
End point description |
Geometric mean concentrations (GMCs) of MenC-polysaccharide specific IgA in saliva prior to (T0) the MenC conjugate booster vaccination.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T0
|
||||||||||||||||
|
|||||||||||||||||
| Notes [50] - Only participants with sufficient amounts of saliva and serum available to perform all measurements. [51] - Only participants with sufficient amounts of saliva and serum available to perform all measurements. [52] - Only participants with sufficient amounts of saliva and serum available to perform all measurements. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgA in saliva 10 vs. 12 at T0 | ||||||||||||||||
Statistical analysis description |
Comparisons of GMC MenC-PS specific IgA in saliva at T0 between age groups were made using the Mann–Whitney U test.
All p-values for these analyses were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
167
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.159 [53] | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [53] - All p-values for these analyses were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgA in saliva 10 vs. 15 at T0 | ||||||||||||||||
Statistical analysis description |
Comparisons of GMC MenC-PS specific IgA in saliva at T0 between age groups were made using the Mann–Whitney U test.
All p-values for these analyses were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
156
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [54] | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [54] - All p-values for these analyses were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgA in saliva 12 vs. 15 at T0 | ||||||||||||||||
Statistical analysis description |
Comparisons of GMC MenC-PS specific IgA in saliva at T0 between age groups were made using the Mann–Whitney U test.
All p-values for these analyses were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
161
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.03 [55] | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [55] - All p-values for these analyses were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
GMC MenC-PS specific IgA in saliva at T1 | ||||||||||||||||
End point description |
Geometric mean concentrations (GMCs) of MenC-polysaccharide specific IgA in saliva 1 Month (T1) after the MenC conjugate booster vaccination.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T1
|
||||||||||||||||
|
|||||||||||||||||
| Notes [56] - Only participants with sufficient amounts of saliva and serum available to perform all measurements. [57] - Only participants with sufficient amounts of saliva and serum available to perform all measurements. [58] - Only participants with sufficient amounts of saliva and serum available to perform all measurements. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgA in saliva 10 vs. 12 at T1 | ||||||||||||||||
Statistical analysis description |
Comparisons of GMC MenC-PS specific IgA in saliva at T1 between age groups were made using linear regression analyses with correction for values at T0. All p-values for these analyses were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
169
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [59] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [59] - All p-values for these analyses were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgA in saliva 10 vs. 15 at T1 | ||||||||||||||||
Statistical analysis description |
Comparisons of GMC MenC-PS specific IgA in saliva at T1 between age groups were made using linear regression analyses with correction for values at T0. All p-values for these analyses were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
158
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [60] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [60] - All p-values for these analyses were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgA in saliva 12 vs. 15 at T1 | ||||||||||||||||
Statistical analysis description |
Comparisons of GMC MenC-PS specific IgA in saliva at T1 between age groups were made using linear regression analyses with correction for values at T0. All p-values for these analyses were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
161
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 1 [61] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [61] - All p-values for these analyses were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
GMC MenC-PS specific IgA in saliva at T2 | ||||||||||||||||
End point description |
Geometric mean concentrations (GMCs) of MenC-polysaccharide specific IgA in saliva 1 Year (T2) after the MenC conjugate booster vaccination.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T2
|
||||||||||||||||
|
|||||||||||||||||
| Notes [62] - Only participants with sufficient amounts of saliva and serum available to perform all measurements. [63] - Only participants with sufficient amounts of saliva and serum available to perform all measurements. [64] - Only participants with sufficient amounts of saliva and serum available to perform all measurements. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgA in saliva 10 vs. 12 at T2 | ||||||||||||||||
Statistical analysis description |
Comparisons of GMC MenC-PS specific IgA in saliva at T2 between age groups were made using linear regression analyses with correction for values at T0. All p-values for these analyses were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
169
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.006 [65] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [65] - All p-values for these analyses were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgA in saliva 10 vs. 15 at T2 | ||||||||||||||||
Statistical analysis description |
Comparisons of GMC MenC-PS specific IgA in saliva at T2 between age groups were made using linear regression analyses with correction for values at T0. All p-values for these analyses were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
158
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.057 [66] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [66] - All p-values for these analyses were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgA in saliva 12 vs. 15 at T2 | ||||||||||||||||
Statistical analysis description |
Comparisons of GMC MenC-PS specific IgA in saliva at T2 between age groups were made using linear regression analyses with correction for values at T0. All p-values for these analyses were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
161
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 1 [67] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [67] - All p-values for these analyses were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
GMC MenC-PS specific IgG1 antibodies at T0 | ||||||||||||||||
End point description |
Geometric Mean Concentrations (GMCs) of Meningococcal Serogroup C Polysaccharide (MenC-PS) Specific Immunoglobulin G Subclass 1 (IgG1).
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T0
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG1 10 vs. 12 at T0 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG subclass 1 were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
12 year olds v 10 year olds
|
||||||||||||||||
Number of subjects included in analysis |
182
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 1 [68] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [68] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG1 10 vs. 15 at T0 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG subclass 1 were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
177
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 1 [69] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [69] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG1 12 vs. 15 at T0 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG subclass 1 were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
177
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 1 [70] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [70] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
GMC MenC-PS specific IgG1 antibodies at T1 | ||||||||||||||||
End point description |
Geometric Mean Concentrations (GMCs) of Meningococcal Serogroup C Polysaccharide (MenC-PS) Specific Immunoglobulin G Subclass 1 (IgG1).
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T1
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG1 10 vs. 12 at T1 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG subclass 1 were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
178
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.015 [71] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [71] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG1 10 vs. 15 at T1 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG subclass 1 were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
173
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 1 [72] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [72] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG1 12 vs. 15 at T1 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG subclass 1 were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
175
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.174 [73] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [73] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
GMC MenC-PS specific IgG1 antibodies at T2 | ||||||||||||||||
End point description |
Geometric Mean Concentrations (GMCs) of Meningococcal Serogroup C Polysaccharide (MenC-PS) Specific Immunoglobulin G Subclass 1 (IgG1).
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T2
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG1 10 vs. 12 at T2 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG subclass 1 were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
174
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [74] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [74] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG1 10 vs. 15 at T2 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG subclass 1 were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
168
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [75] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [75] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG1 12 vs. 15 at T2 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG subclass 1 were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
172
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.531 [76] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [76] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
GMC MenC-PS specific IgG2 antibodies at T0 | ||||||||||||||||
End point description |
Geometric Mean Concentrations (GMCs) of Meningococcal Serogroup C Polysaccharide (MenC-PS) Specific Immunoglobulin G Subclass 2 (IgG2).
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T0
|
||||||||||||||||
|
|||||||||||||||||
| Notes [77] - Concentration IgG2 too low to measure in nine participants; GMC IgG2 presented from 82 participants [78] - Concentration IgG2 too low to measure in five participants; GMC IgG2 presented from 86 participants. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG2 10 vs. 12 at T0 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG subclass 2 were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
168
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.024 [79] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [79] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG2 10 vs. 15 at T0 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG subclass 2 were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
168
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.003 [80] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [80] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG2 12 vs. 15 at T0 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG subclass 2 were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
172
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 1 [81] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [81] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
GMC MenC-PS specific IgG2 antibodies at T1 | ||||||||||||||||
End point description |
Geometric Mean Concentrations (GMCs) of Meningococcal Serogroup C Polysaccharide (MenC-PS) Specific Immunoglobulin G Subclass 2 (IgG2).
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T1
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG2 10 vs. 12 at T1 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG subclass 2 were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
178
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.003 [82] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [82] - * P-values were adjusted for three comparisons with Bonferroni |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG2 10 vs. 15 at T1 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG subclass 2 were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
173
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [83] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [83] - * P-values were adjusted for three comparisons with Bonferroni |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG2 12 vs. 15 at T1 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG subclass 2 were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
175
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 1 [84] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [84] - * P-values were adjusted for three comparisons with Bonferroni |
|||||||||||||||||
|
|||||||||||||||||
End point title |
GMC MenC-PS specific IgG2 antibodies at T2 | ||||||||||||||||
End point description |
Geometric Mean Concentrations (GMCs) of Meningococcal Serogroup C Polysaccharide (MenC-PS) Specific Immunoglobulin G Subclass 2 (IgG2).
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T2
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG2 10 vs. 12 at T2 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG subclass 2 were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
* P-values were adjusted for three comparisons with Bonferroni correction. Extensive results of the crude a
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
174
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [85] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [85] - * P-values were adjusted for three comparisons with Bonferroni |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG2 10 vs. 15 at T2 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG subclass 2 were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
* P-values were adjusted for three comparisons with Bonferroni correction. Extensive results of the crude a
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
168
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [86] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [86] - * P-values were adjusted for three comparisons with Bonferroni |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG2 12 vs. 15 at T2 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG subclass 2 were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
* P-values were adjusted for three comparisons with Bonferroni correction. Extensive results of the crude a
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
172
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.531 [87] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [87] - * P-values were adjusted for three comparisons with Bonferroni |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Ratio MenC-PS specific IgG1/IgG2 antibodies at T0 | ||||||||||||||||
End point description |
Ratio of the Geometric Mean Concentrations (GMCs) of Meningococcal Serogroup C Polysaccharide (MenC-PS) Specific Immunoglobulin G Subclass 1 (IgG1) and Immunoglobulin G Subclass 2 (IgG2) at T0.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T0
|
||||||||||||||||
|
|||||||||||||||||
| Notes [88] - Concentration IgG2 too low to measure in nine participants; ratio presented from 82 participants [89] - Concentration IgG2 too low to measure in five participants; ratio presented from 86 participants |
|||||||||||||||||
Statistical analysis title |
MenC-PS IgG1/IgG2 subclass ratio 10 vs. 12 at T0 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in MenC-PS specific IgG1 / IgG2 subclass ratio were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
168
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.027 [90] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [90] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
MenC-PS IgG1/IgG2 subclass ratio 10 vs. 15 at T0 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in MenC-PS specific IgG1 / IgG2 subclass ratio were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
168
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [91] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [91] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
MenC-PS IgG1/IgG2 subclass ratio 12 vs. 15 at T0 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in MenC-PS specific IgG1 / IgG2 subclass ratio were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
172
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.522 [92] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [92] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Ratio MenC-PS specific IgG1/IgG2 antibodies at T1 | ||||||||||||||||
End point description |
Ratio of the Geometric Mean Concentrations (GMCs) of Meningococcal Serogroup C Polysaccharide (MenC-PS) Specific Immunoglobulin G Subclass 1 (IgG1) and Immunoglobulin G Subclass 2 (IgG2) at T1.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T1
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
MenC-PS IgG1/IgG2 subclass ration 10 vs. 12 at T1 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in MenC-PS specific IgG1 / IgG2 subclass ratio were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
178
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.255 [93] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [93] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
MenC-PS IgG1/IgG2 subclass ration 10 vs. 15 at T1 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in MenC-PS specific IgG1 / IgG2 subclass ratio were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
173
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.054 [94] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [94] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
MenC-PS IgG1/IgG2 subclass ration 12 vs. 15 at T1 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in MenC-PS specific IgG1 / IgG2 subclass ratio were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
175
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.276 [95] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [95] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Ratio MenC-PS specific IgG1/IgG2 antibodies at T2 | ||||||||||||||||
End point description |
Ratio of the Geometric Mean Concentrations (GMCs) of Meningococcal Serogroup C Polysaccharide (MenC-PS) Specific Immunoglobulin G Subclass 1 (IgG1) and Immunoglobulin G Subclass 2 (IgG2) at T2.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T2
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
MenC-PS IgG1/IgG2 subclass ratio 10 vs. 12 at T2 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in MenC-PS specific IgG1 / IgG2 subclass ratio were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
174
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.969 [96] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [96] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
MenC-PS IgG1/IgG2 subclass ratio 10 vs. 15 at T2 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in MenC-PS specific IgG1 / IgG2 subclass ratio were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
168
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.156 [97] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [97] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
MenC-PS IgG1/IgG2 subclass ratio 12 vs. 15 at T2 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in MenC-PS specific IgG1 / IgG2 subclass ratio were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
172
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.297 [98] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [98] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||||||
End point title |
Mean MenC-PS IgG avidity index age 10 | ||||||||||||||||||||
End point description |
Meningococcal Serogroup C Polysaccharide Specific Immunoglobulin G (IgG) Avidity Indices (AI). Mean avidity indices per age group prior to (T0) and 1 month (T1) and 1 year (T2) after the MenC conjugate booster. Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included in the analyses (44 10-year-olds, 49 12-year-olds and 60 15-year-olds). Serum samples were diluted to a concentration of 25 ng/ml. Avidity index = (amount of IgG still bound after treatment with 0.5 M NH4SCN/amount of IgG with PBS) x 100.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
T0, T1, T2 and T3 of age group 10 years old.
|
||||||||||||||||||||
|
|||||||||||||||||||||
| Notes [99] - Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included. [100] - Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included. [101] - Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included. [102] - Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included. |
|||||||||||||||||||||
Statistical analysis title |
Avidity index age 10 T0 vs. T1 | ||||||||||||||||||||
Statistical analysis description |
Paired sample t-test avidity index age group 10 year old for T0 and T1.
|
||||||||||||||||||||
Comparison groups |
Age group 10 at T0 v Age group 10 at T1
|
||||||||||||||||||||
Number of subjects included in analysis |
87
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||||||
P-value |
= 0.3127 | ||||||||||||||||||||
Method |
paired sample t-test | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Statistical analysis title |
Avidity index age 10 T0 vs. T2 | ||||||||||||||||||||
Statistical analysis description |
Paired sample t-test avidity index age group 10 year old for T0 and T2.
|
||||||||||||||||||||
Comparison groups |
Age group 10 at T0 v Age group 10 at T2
|
||||||||||||||||||||
Number of subjects included in analysis |
86
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||||||
P-value |
= 0.3975 | ||||||||||||||||||||
Method |
paired sample t-test | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Statistical analysis title |
Avidity index age 10 T1 vs. T2 | ||||||||||||||||||||
Statistical analysis description |
Paired sample t-test avidity index age group 10 year old for T1 and T2.
|
||||||||||||||||||||
Comparison groups |
Age group 10 at T2 v Age group 10 at T1
|
||||||||||||||||||||
Number of subjects included in analysis |
85
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||||||
P-value |
= 0.6349 | ||||||||||||||||||||
Method |
paired sample t-test | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Statistical analysis title |
Avidity index age 10 T2 vs. T3 | ||||||||||||||||||||
Statistical analysis description |
Paired sample t-test avidity index age group 10 year old for T2 and T3.
|
||||||||||||||||||||
Comparison groups |
Age group 10 at T2 v Age group 10 at T3
|
||||||||||||||||||||
Number of subjects included in analysis |
64
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||||||
P-value |
= 0.9924 | ||||||||||||||||||||
Method |
paired sample t-test | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
|
|||||||||||||||||||||
End point title |
Mean MenC-PS IgG avidity index age 12 | ||||||||||||||||||||
End point description |
Meningococcal Serogroup C Polysaccharide Specific Immunoglobulin G (IgG) Avidity Indices (AI). Mean avidity indices per age group prior to (T0) and 1 month (T1) and 1 year (T2) after the MenC conjugate booster. Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included in the analyses (44 10-year-olds, 49 12-year-olds and 60 15-year-olds). Serum samples were diluted to a concentration of 25 ng/ml. Avidity index = (amount of IgG still bound after treatment with 0.5 M NH4SCN/amount of IgG with PBS) x 100.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
T0, T1, T2 and T3 of age group 12 years old.
|
||||||||||||||||||||
|
|||||||||||||||||||||
| Notes [103] - Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included. [104] - Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included. [105] - Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included. [106] - Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included. |
|||||||||||||||||||||
Statistical analysis title |
Avidity index age 12 T0 vs. T1 | ||||||||||||||||||||
Statistical analysis description |
Paired sample t-test avidity index age group 12 year old for T0 and T1.
|
||||||||||||||||||||
Comparison groups |
Age group 12 at T0 v Age group 12 at T1
|
||||||||||||||||||||
Number of subjects included in analysis |
97
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||||||
P-value |
= 0.9792 | ||||||||||||||||||||
Method |
paired sample t-test | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Statistical analysis title |
Avidity index age 12 T0 vs. T2 | ||||||||||||||||||||
Statistical analysis description |
Paired sample t-test avidity index age group 12 year old for T0 and T2.
|
||||||||||||||||||||
Comparison groups |
Age group 12 at T0 v Age group 12 at T2
|
||||||||||||||||||||
Number of subjects included in analysis |
97
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||||||
P-value |
= 0.6209 [107] | ||||||||||||||||||||
Method |
paired sample t-test | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
| Notes [107] - not significant |
|||||||||||||||||||||
Statistical analysis title |
Avidity index age 12 T1 vs. T2 | ||||||||||||||||||||
Statistical analysis description |
Paired sample t-test avidity index age group 12 year old for T1 and T2.
|
||||||||||||||||||||
Comparison groups |
Age group 12 at T2 v Age group 12 at T1
|
||||||||||||||||||||
Number of subjects included in analysis |
96
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||||||
P-value |
= 0.5851 | ||||||||||||||||||||
Method |
paired sample t-test | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Statistical analysis title |
Avidity index age 12 T2 vs. T3 | ||||||||||||||||||||
Statistical analysis description |
Paired sample t-test avidity index age group 12 year old for T2 and T3.
|
||||||||||||||||||||
Comparison groups |
Age group 12 at T2 v Age group 12 at T3
|
||||||||||||||||||||
Number of subjects included in analysis |
80
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||||||
P-value |
= 0.5762 | ||||||||||||||||||||
Method |
paired sample t-test | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
|
|||||||||||||||||||||
End point title |
Mean MenC-PS IgG avidity index age 15 | ||||||||||||||||||||
End point description |
Meningococcal Serogroup C Polysaccharide Specific Immunoglobulin G (IgG) Avidity Indices (AI). Mean avidity indices per age group prior to (T0) and 1 month (T1) and 1 year (T2) after the MenC conjugate booster. Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included in the analyses (44 10-year-olds, 49 12-year-olds and 60 15-year-olds). Serum samples were diluted to a concentration of 25 ng/ml. Avidity index = (amount of IgG still bound after treatment with 0.5 M NH4SCN/amount of IgG with PBS) x 100.
|
||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||
End point timeframe |
T0, T1, T2 and T3 of age group 15 years old.
|
||||||||||||||||||||
|
|||||||||||||||||||||
| Notes [108] - Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included. [109] - Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included. [110] - Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included. [111] - Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included. |
|||||||||||||||||||||
Statistical analysis title |
Avidity index age 15 T0 vs. T1 | ||||||||||||||||||||
Statistical analysis description |
Paired sample t-test avidity index age group 15 year old for T0 and T1.
|
||||||||||||||||||||
Comparison groups |
Age group 15 at T0 v Age group 15 at T1
|
||||||||||||||||||||
Number of subjects included in analysis |
120
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||||||
P-value |
= 0.0027 | ||||||||||||||||||||
Method |
paired sample t-test | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Statistical analysis title |
Avidity index age 15 T0 vs. T2 | ||||||||||||||||||||
Statistical analysis description |
Paired sample t-test avidity index age group 15 year old for T0 and T2.
|
||||||||||||||||||||
Comparison groups |
Age group 15 at T0 v Age group 15 at T2
|
||||||||||||||||||||
Number of subjects included in analysis |
119
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||||||
P-value |
= 0.044 | ||||||||||||||||||||
Method |
paired sample t-test | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Statistical analysis title |
Avidity index age 15 T1 vs. T2 | ||||||||||||||||||||
Statistical analysis description |
Paired sample t-test avidity index age group 15 year old for T1 and T2.
|
||||||||||||||||||||
Comparison groups |
Age group 15 at T2 v Age group 15 at T1
|
||||||||||||||||||||
Number of subjects included in analysis |
119
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||||||
P-value |
= 0.0006 | ||||||||||||||||||||
Method |
paired sample t-test | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
Statistical analysis title |
Avidity index age 15 T2 vs. T3 | ||||||||||||||||||||
Statistical analysis description |
Paired sample t-test avidity index age group 15 year old for T2 and T3.
|
||||||||||||||||||||
Comparison groups |
Age group 15 at T2 v Age group 15 at T3
|
||||||||||||||||||||
Number of subjects included in analysis |
84
|
||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||||||
P-value |
= 0.0029 | ||||||||||||||||||||
Method |
paired sample t-test | ||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||
|
|||||||||||||||||
End point title |
GMC of Tetanus Toxoid specific IgG at T0 | ||||||||||||||||
End point description |
Geometric Mean Concentrations (GMCs) of Tetanus Toxoid (TT) Specific Immunoglobulin G (IgG) prior to (T0) the Meningococcal Serogroup C Tetanus Toxoid Conjugate Booster.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T0
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
GMT TT IgG levels 10 vs. 12 at T0 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of TT-specific IgG were determined with linear regression analyses, adjusting for concentrations at T0.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
182
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [112] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [112] - * P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMT TT IgG levels 10 vs. 15 at T0 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of TT-specific IgG were determined with linear regression analyses, adjusting for concentrations at T0.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
177
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [113] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [113] - * P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMT TT IgG levels 12 vs.15 at T0 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of TT-specific IgG were determined with linear regression analyses, adjusting for concentrations at T0.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
177
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [114] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [114] - * P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
GMC of Tetanus Toxoid specific IgG at T1 | ||||||||||||||||
End point description |
Geometric Mean Concentrations (GMCs) of Tetanus Toxoid (TT) Specific Immunoglobulin G (IgG) 1 Month (T1) after the Meningococcal Serogroup C Tetanus Toxoid Conjugate Booster.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T1
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
GMC TT IgG levels 10 vs. 12 at T1 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of TT-specific IgG were determined with linear regression analyses, adjusting for concentrations at T0.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
178
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.069 [115] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [115] - * P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC TT IgG levels 10 vs. 15 at T1 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of TT-specific IgG were determined with linear regression analyses, adjusting for concentrations at T0.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
173
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.213 [116] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [116] - * P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC TT IgG levels 12 vs. 15 at T1 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of TT-specific IgG were determined with linear regression analyses, adjusting for concentrations at T0.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
175
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 1 [117] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [117] - * P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
GMC of Tetanus Toxoid specific IgG at T2 | ||||||||||||||||
End point description |
Geometric Mean Concentrations (GMCs) of Tetanus Toxoid (TT) Specific Immunoglobulin G (IgG) 1 Year (T2) after the Meningococcal Serogroup C Tetanus Toxoid Conjugate Booster.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T2
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
GMC TT IgG levels 10 vs. 12 at T2 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of TT-specific IgG were determined with linear regression analyses, adjusting for concentrations at T0.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
174
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.006 [118] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [118] - * P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC TT IgG levels 10 vs. 15 at T2 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of TT-specific IgG were determined with linear regression analyses, adjusting for concentrations at T0.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
168
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.153 [119] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [119] - * P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC TT IgG levels 12 vs. 15 at T2 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of TT-specific IgG were determined with linear regression analyses, adjusting for concentrations at T0.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
172
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.186 [120] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [120] - * P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Ratio of GMC TT IgG levels T1/T0 | ||||||||||||||||
End point description |
Ratio of the Geometric Mean Concentrations (GMCs) of Tetanus Toxoid (TT) Specific IgG prior to (T0) and 1 month (T1) after the Menongococcal Serogroup C tetanus Toxoid Conjugate Booster.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T1 versus T0
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Ratio of GMC TT IgG levels T1/T0 10 vs. 12 years | ||||||||||||||||
Statistical analysis description |
GMC ratios indicate the level of increase (T1/T0) of Tetanus Toxiod specific IgG between time points. Differences in GMC ratios between groups were determined with independent sample t-tests.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
178
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [121] | ||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [121] - * P-values were adjusted for three comparisons with Bonfe |
|||||||||||||||||
Statistical analysis title |
Ratio of GMC TT IgG levels T1/T0 10 vs. 15 years | ||||||||||||||||
Statistical analysis description |
GMC ratios indicate the level of increase (T1/T0) of Tetanus Toxiod specific IgG between time points. Differences in GMC ratios between groups were determined with independent sample t-tests.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
173
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [122] | ||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [122] - * P-values were adjusted for three comparisons with Bonfe |
|||||||||||||||||
Statistical analysis title |
Ratio of GMC TT IgG levels T1/T0 12 vs. 15 years | ||||||||||||||||
Statistical analysis description |
GMC ratios indicate the level of increase (T1/T0) of Tetanus Toxiod specific IgG between time points. Differences in GMC ratios between groups were determined with independent sample t-tests.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
175
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [123] | ||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [123] - * P-values were adjusted for three comparisons with Bonfe |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Ratio of GMC TT IgG levels T1/T2 | ||||||||||||||||
End point description |
Ratio of the Geometric Mean Concentrations (GMCs) of Tetanus Toxoid (TT) Specific IgG 1 month (T1) and 1 year (T2) after the Menongococcal Serogroup C tetanus Toxoid Conjugate Booster.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T1 versus T2
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Ratio of GMC TT IgG levels T1/T2 10 vs. 12 years | ||||||||||||||||
Statistical analysis description |
GMC ratios indicate the level of decrease (T1/T2) of Tetanus Toxoid (TT) specific IgG between time points. Differences in GMC ratios between groups were determined with independent sample t-tests.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
174
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.048 [124] | ||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [124] - * P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
Ratio of GMC TT IgG levels T1/T2 10 vs. 15 years | ||||||||||||||||
Statistical analysis description |
GMC ratios indicate the level of decrease (T1/T2) of Tetanus Toxoid (TT) specific IgG between time points. Differences in GMC ratios between groups were determined with independent sample t-tests.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
168
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.001 [125] | ||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [125] - * P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
Ratio of GMC TT IgG levels T1/T2 12 vs. 15 years | ||||||||||||||||
Statistical analysis description |
GMC ratios indicate the level of decrease (T1/T2) of Tetanus Toxoid (TT) specific IgG between time points. Differences in GMC ratios between groups were determined with independent sample t-tests.
* P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
172
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.921 [126] | ||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [126] - * P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Mean MenC-PS IgG avidity index T0 | ||||||||||||||||
End point description |
Meningococcal Serogroup C Polysaccharide Specific Immunoglobulin G (IgG) Avidity Indices (AI). Mean avidity indices per age group prior to (T0) the MenC conjugate booster. Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included in the analyses (44 10-year-olds, 49 12-year-olds and 60 15-year-olds). Serum samples were diluted to a concentration of 25 ng/ml. Avidity index = (amount of IgG still bound after treatment with 0.5 M NH4SCN/amount of IgG with PBS) x 100.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T0
|
||||||||||||||||
|
|||||||||||||||||
| Notes [127] - Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included. [128] - Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included. [129] - Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included. |
|||||||||||||||||
Statistical analysis title |
Avidity index T0 10 vs. 12 years old | ||||||||||||||||
Statistical analysis description |
T-test on the mean avidity index at T0 for age groups 10 and 12 years old.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
93
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.6342 | ||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Avidity index T0 10 vs. 15 years old | ||||||||||||||||
Statistical analysis description |
T-test on the mean avidity index at T0 for age groups 10 and 15 years old.
|
||||||||||||||||
Comparison groups |
15 year olds v 10 year olds
|
||||||||||||||||
Number of subjects included in analysis |
104
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.2076 | ||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Avidity index T0 12 vs. 15 years old | ||||||||||||||||
Statistical analysis description |
T-test on the mean avidity index at T0 for age groups 12 and 15 years old.
|
||||||||||||||||
Comparison groups |
12 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
109
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.1564 | ||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||
Confidence interval |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Mean MenC-PS IgG avidity index T1 | ||||||||||||||||
End point description |
Meningococcal Serogroup C Polysaccharide Specific Immunoglobulin G (IgG) Avidity Indices (AI). Mean avidity indices per age group 1 month after the MenC conjugate booster (T1). Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included in the analyses. Serum samples were diluted to a concentration of 25 ng/ml. Avidity index = (amount of IgG still bound after treatment with 0.5 M NH4SCN/amount of IgG with PBS) x 100.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T1
|
||||||||||||||||
|
|||||||||||||||||
| Notes [130] - Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included. [131] - Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included. [132] - Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included. |
|||||||||||||||||
Statistical analysis title |
Avidity index T1 10 vs. 12 years old | ||||||||||||||||
Statistical analysis description |
T-test of mean avidity index at T1 for groups 10 and 12 years old.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
91
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.1701 | ||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Avidity index T1 10 vs. 15 years old | ||||||||||||||||
Statistical analysis description |
T-test of mean avidity index at T1 for groups 10 and 15 years old.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
103
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.0131 | ||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Avidity index T1 12 vs. 15 years old | ||||||||||||||||
Statistical analysis description |
T-test of mean avidity index at T1 for groups 12 and 15 years old.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
108
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.2148 | ||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||
Confidence interval |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Mean MenC-PS IgG avidity index T2 | ||||||||||||||||
End point description |
Meningococcal Serogroup C Polysaccharide Specific Immunoglobulin G (IgG) Avidity Indices (AI). Mean avidity indices per age group 1 year after the MenC conjugate booster (T2). Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included in the analyses. Serum samples were diluted to a concentration of 25 ng/ml. Avidity index = (amount of IgG still bound after treatment with 0.5 M NH4SCN/amount of IgG with PBS) x 100.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T2
|
||||||||||||||||
|
|||||||||||||||||
| Notes [133] - Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included. [134] - Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included. [135] - Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included. |
|||||||||||||||||
Statistical analysis title |
Avidity index T2 10 vs. 12 years old | ||||||||||||||||
Statistical analysis description |
T-test of mean avidity index at T2 for groups 10 and 12 years old.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
90
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.1105 | ||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Avidity index T2 10 vs. 15 years old | ||||||||||||||||
Statistical analysis description |
T-test of mean avidity index at T2 for groups 10 and 15 years old.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
101
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.3533 | ||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Avidity index T2 12 vs. 15 years old | ||||||||||||||||
Statistical analysis description |
T-test of mean avidity index at T2 for groups 12 and 15 years old.
|
||||||||||||||||
Comparison groups |
12 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
107
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.4775 | ||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||
Confidence interval |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Mean MenC-PS IgG avidity index T3 | ||||||||||||||||
End point description |
Meningococcal Serogroup C Polysaccharide Specific Immunoglobulin G (IgG) Avidity Indices (AI). Mean avidity indices per age group 3 years after the MenC conjugate booster (T3). Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included in the analyses. Serum samples were diluted to a concentration of 25 ng/ml. Avidity index = (amount of IgG still bound after treatment with 0.5 M NH4SCN/amount of IgG with PBS) x 100.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T3
|
||||||||||||||||
|
|||||||||||||||||
| Notes [136] - Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included. [137] - Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included. [138] - Only serum samples from participants with an IgG concentration of >=0.25 mg/ml at T0 were included. |
|||||||||||||||||
Statistical analysis title |
Avidity index T3 10 vs. 12 years old | ||||||||||||||||
Statistical analysis description |
T-test of mean avidity index at T3 for age groups 10 and 12 years old.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
54
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.2658 | ||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Avidity index T3 10 vs. 15 years old | ||||||||||||||||
Statistical analysis description |
T-test of mean avidity index at T3 for age groups 10 and 15 years old.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
47
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.5705 | ||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Avidity index T3 12 vs. 15 years old | ||||||||||||||||
Statistical analysis description |
T-test of mean avidity index at T3 for age groups 12 and 15 years old.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
57
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.5701 | ||||||||||||||||
Method |
t-test, 2-sided | ||||||||||||||||
Confidence interval |
|||||||||||||||||
|
|||||||||||||||||
End point title |
GMC MenC-PS specific IgG antibodies at T3 | ||||||||||||||||
End point description |
Geometric Mean Concentrations (GMCs) of Meningococcal Serogroup C Polysaccharide (MenC-PS) Specific Immunoglobulin G (IgG) 3 years (T3) after the MenC Conjugate Booster.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T3
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG 10 vs. 12 at T3 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC MenC-PS IgG at T3 were determined with linear regression analyses, adjusting for titers and concentrations before the booster vaccination.
All P-values were adjusted for three comparisons with the Bonferroni correction.
|
||||||||||||||||
Comparison groups |
12 year olds v 10 year olds
|
||||||||||||||||
Number of subjects included in analysis |
141
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [139] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [139] - All P-values were adjusted for three comparisons with the Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG 10 vs. 15 at T3 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC MenC-PS IgG at T3 were determined with linear regression analyses, adjusting for titers and concentrations before the booster vaccination.
All P-values were adjusted for three comparisons with the Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
124
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [140] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [140] - All P-values were adjusted for three comparisons with the Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG 12 vs. 15 at T3 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC MenC-PS IgG at T3 were determined with linear regression analyses, adjusting for titers and concentrations before the booster vaccination.
All P-values were adjusted for three comparisons with the Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
133
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.267 [141] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [141] - All P-values were adjusted for three comparisons with the Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
GMC of Tetanus Toxoid specific IgG at T3 | ||||||||||||||||
End point description |
Geometric Mean Concentrations (GMCs) of Tetanus Toxoid (TT) Specific Immunoglobulin G (IgG) 3 years (T3) after the Meningococcal Serogroup C Tetanus Toxoid Conjugate Booster.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T3
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
GMC Tetanus Toxoid specific IgG 10 vs. 12 at T3 | ||||||||||||||||
Statistical analysis description |
Differences in Geometric Mean Concentrations (GMCs) of Tetanus Toxoid (TT) Specific Immunoglobulin G (IgG) 3 years (T3) after the Meningococcal Serogroup C Tetanus Toxoid Conjugate Booster were determined with linear regression, adjusting for concentrations before the booster vaccination. All P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
141
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [142] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [142] - All P-values were adjusted for three comparisons with the Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC Tetanus Toxoid specific IgG 10 vs. 15 at T3 | ||||||||||||||||
Statistical analysis description |
Differences in Geometric Mean Concentrations (GMCs) of Tetanus Toxoid (TT) Specific Immunoglobulin G (IgG) 3 years (T3) after the Meningococcal Serogroup C Tetanus Toxoid Conjugate Booster were determined with linear regression, adjusting for concentrations before the booster vaccination. All P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
124
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.001 [143] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [143] - All P-values were adjusted for three comparisons with the Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC Tetanus Toxoid specific IgG 12 vs. 15 at T3 | ||||||||||||||||
Statistical analysis description |
Differences in Geometric Mean Concentrations (GMCs) of Tetanus Toxoid (TT) Specific Immunoglobulin G (IgG) 3 years (T3) after the Meningococcal Serogroup C Tetanus Toxoid Conjugate Booster were determined with linear regression, adjusting for concentrations before the booster vaccination. All P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
133
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [144] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [144] - All P-values were adjusted for three comparisons with the Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
GMC MenC-PS specific IgG1 antibodies at T3 | ||||||||||||||||
End point description |
Geometric Mean Concentrations (GMCs) of Meningococcal Serogroup C Polysaccharide (MenC-PS) Specific Immunoglobulin G Subclass 1 (IgG1) 3 years (T3) after booster vaccination.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T3
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG1 10 vs. 12 at T3 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG subclass 1 were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
141
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [145] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [145] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG1 10 vs. 15 at T3 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG subclass 1 were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
124
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [146] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [146] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG1 12 vs. 15 at T3 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG subclass 1 were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
133
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.354 [147] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [147] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
GMC MenC-PS specific IgG2 antibodies at T3 | ||||||||||||||||
End point description |
Geometric Mean Concentrations (GMCs) of Meningococcal Serogroup C Polysaccharide (MenC-PS) Specific Immunoglobulin G Subclass 2 (IgG2) 3 years (T3) after booster vaccination.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T3
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG2 10 vs. 12 at T3 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG subclass 2 were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
141
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [148] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [148] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG2 10 vs. 15 at T3 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG subclass 2 were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
124
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
< 0.001 [149] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [149] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
GMC MenC-PS specific IgG2 12 vs. 15 at T3 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in GMC of MenC-PS specific IgG subclass 2 were determined with linear regression analyses, adjusting for concentrations and ratios at T0.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
133
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.297 [150] | ||||||||||||||||
Method |
Regression, Linear | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [150] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Ratio MenC-PS specific IgG1/IgG2 antibodies at T3 | ||||||||||||||||
End point description |
Ratio of the Geometric Mean Concentrations (GMCs) of Meningococcal Serogroup C Polysaccharide (MenC-PS) Specific Immunoglobulin G Subclass 1 (IgG1) and Immunoglobulin G Subclass 2 (IgG2) at T3.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T3
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Ratio MenC-PS IgG1/IgG levels 10 vs. 12 at T3 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in MenC-PS specific IgG1 / IgG2 subclass ratio were determined with independent sample t-test.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
141
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.447 [151] | ||||||||||||||||
Method |
independent sample t-test | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [151] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
Ratio MenC-PS IgG1/IgG levels 10 vs. 15 at T3 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in MenC-PS specific IgG1 / IgG2 subclass ratio were determined with independent sample t-test.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
124
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.003 [152] | ||||||||||||||||
Method |
independent sample t-test | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [152] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
Statistical analysis title |
Ratio MenC-PS IgG1/IgG levels 12 vs. 15 at T3 | ||||||||||||||||
Statistical analysis description |
Differences between age groups in MenC-PS specific IgG1 / IgG2 subclass ratio were determined with independent sample t-test.
P-values were adjusted for three comparisons with Bonferroni correction.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
133
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.06 [153] | ||||||||||||||||
Method |
independent sample t-test | ||||||||||||||||
Confidence interval |
|||||||||||||||||
| Notes [153] - P-values were adjusted for three comparisons with Bonferroni correction. |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Decay of SBA titer below 8 (50% predicted interval) | ||||||||||||||||
End point description |
Predicted time after the meningococcal serogroup C conjugated to tetanus toxoid (MenC-TT) booster vaccination to fall below an rSBA titer of 8 for the three age groups estimated by the bi-exponential decay model. Calculated median duration of protection (50% predicted interval).
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T0 - T3
|
||||||||||||||||
|
|||||||||||||||||
| Notes [154] - Samples from T0 to T3 were used. [155] - Samples from T0 to T3 were used. [156] - Samples from T0 to T3 were used. |
|||||||||||||||||
| No statistical analyses for this end point | |||||||||||||||||
|
|||||||||||||||||
End point title |
Decay of SBA titer below 8 (5% predicted interval) | ||||||||||||||||
End point description |
Predicted time after the meningococcal serogroup C conjugated to tetanus toxoid (MenC-TT) booster vaccination to fall below an rSBA titer of 8 for the three age groups estimated by the bi-exponential decay model. The estimated minimal duration of protection after this booster vaccination (5% predicted interval).
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T0-T3
|
||||||||||||||||
|
|||||||||||||||||
| Notes [157] - Samples from T0 to T3 were used. [158] - Samples from T0 to T3 were used. [159] - Samples from T0 to T3 were used. |
|||||||||||||||||
| No statistical analyses for this end point | |||||||||||||||||
|
|||||||||||||||||
End point title |
Decay of SBA titer below 128 (50% predicted interval) | ||||||||||||||||
End point description |
Predicted time after the meningococcal serogroup C conjugated to tetanus toxoid (MenC-TT) booster vaccination to fall below an rSBA titer of 128 for the three age groups estimated by the bi-exponential decay model. Calculated median duration of protection (50% predicted interval).
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T0-T3
|
||||||||||||||||
|
|||||||||||||||||
| Notes [160] - Samples from T0 to T3 were used. [161] - Samples from T0 to T3 were used. [162] - Samples from T0 to T3 were used. |
|||||||||||||||||
| No statistical analyses for this end point | |||||||||||||||||
|
|||||||||||||||||
End point title |
Decay of SBA titer below 128 (5% predicted interval) | ||||||||||||||||
End point description |
Predicted time after the meningococcal serogroup C conjugated to tetanus toxoid (MenC-TT) booster vaccination to fall below an rSBA titer of 128 for the three age groups estimated by the bi-exponential decay model. The estimated minimal duration of protection after this booster vaccination (5% predicted interval).
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T0-T3
|
||||||||||||||||
|
|||||||||||||||||
| Notes [163] - Samples from T0 to T3 were used. [164] - Samples from T0 to T3 were used. [165] - Samples from T0 to T3 were used. |
|||||||||||||||||
| No statistical analyses for this end point | |||||||||||||||||
|
|||||||||||||||||
End point title |
Men-C PS specific IgA memory B-cell responses at T0 | ||||||||||||||||
End point description |
Frequency of circulating MenC-PS-specific IgA memory B cells prior to (T0) the MenC conjugate booster vaccination. Geometric mean number of MenC-specific memory B cells per 100,000 B cells
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T0
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Men-C PS IgA memory B cells 10 vs. 12 at T0 | ||||||||||||||||
Statistical analysis description |
Mann-Whitney U test on circulating MenC-PS-specific IgA memory B cells prior to (T0) the MenC conjugate booster vaccination. Geometric mean number of MenC-specific memory B cells per 100,000 B cells.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
16
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.7602 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Men-C PS IgA memory B cells 10 vs. 15 at T0 | ||||||||||||||||
Statistical analysis description |
Mann-Whitney U test on circulating MenC-PS-specific IgA memory B cells prior to (T0) the MenC conjugate booster vaccination. Geometric mean number of MenC-specific memory B cells per 100,000 B cells.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
15
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
> 0.9999 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Men-C PS IgA memory B cells 12 vs. 15 at T0 | ||||||||||||||||
Statistical analysis description |
Mann-Whitney U test on circulating MenC-PS-specific IgA memory B cells prior to (T0) the MenC conjugate booster vaccination. Geometric mean number of MenC-specific memory B cells per 100,000 B cells.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
19
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.7942 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Men-C PS specific IgA memory B-cell responses at T1 | ||||||||||||||||
End point description |
Frequency of circulating MenC-PS-specific IgA memory B cells 1 month (T1) after the MenC conjugate booster vaccination. Geometric mean number of MenC-specific memory B cells per 100,000 B cells
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T1
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Men-C PS IgA memory B cells 10 vs. 12 at T1 | ||||||||||||||||
Statistical analysis description |
Mann-Whitney U test on circulating MenC-PS-specific IgA memory B cells 1 month (T1) after the MenC conjugate booster vaccination. Geometric mean number of MenC-specific memory B cells per 100,000 B cells.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
18
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.0165 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Men-C PS IgA memory B cells 10 vs. 15 at T1 | ||||||||||||||||
Statistical analysis description |
Mann-Whitney U test on circulating MenC-PS-specific IgA memory B cells 1 month (T1) after the MenC conjugate booster vaccination. Geometric mean number of MenC-specific memory B cells per 100,000 B cells.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
15
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.0401 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Men-C PS IgA memory B cells 12 vs. 15 at T1 | ||||||||||||||||
Statistical analysis description |
Mann-Whitney U test on circulating MenC-PS-specific IgA memory B cells 1 month (T1) after the MenC conjugate booster vaccination. Geometric mean number of MenC-specific memory B cells per 100,000 B cells.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
19
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.5304 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Men-C PS specific IgA memory B-cell responses at T2 | ||||||||||||||||
End point description |
Frequency of circulating MenC-PS-specific IgA memory B cells 1 year (T2) after the MenC conjugate booster vaccination. Geometric mean number of MenC-specific memory B cells per 100,000 B cells
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T2
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Men-C PS IgA memory B cells 10 vs. 12 at T2 | ||||||||||||||||
Statistical analysis description |
Mann-Whitney U test on circulating MenC-PS-specific IgA memory B cells 1 year (T2) after the MenC conjugate booster vaccination. Geometric mean number of MenC-specific memory B cells per 100,000 B cells.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
16
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.0847 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Men-C PS IgA memory B cells 10 vs. 15 at T2 | ||||||||||||||||
Statistical analysis description |
Mann-Whitney U test on circulating MenC-PS-specific IgA memory B cells 1 year (T2) after the MenC conjugate booster vaccination. Geometric mean number of MenC-specific memory B cells per 100,000 B cells.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
16
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.1346 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Men-C PS IgA memory B cells 12 vs. 15 at T2 | ||||||||||||||||
Statistical analysis description |
Mann-Whitney U test on circulating MenC-PS-specific IgA memory B cells 1 year (T2) after the MenC conjugate booster vaccination. Geometric mean number of MenC-specific memory B cells per 100,000 B cells.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
22
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.96 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Tetanus Toxoid specific IgG memory B-cell responses at T0 | ||||||||||||||||
End point description |
Frequency of circulating Tetanus Toxoid specific IgG memory B cells prior to (T0) the MenC conjugate booster vaccination. Geometric mean number of TT memory B cells per 100,000 B cells
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T0
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Tetanus Toxoid IgG memory B cells 10 vs. 12 at T2 | ||||||||||||||||
Statistical analysis description |
Mann-Whitney U test on circulating Tetanus Toxoid specific IgG memory B cells prior to (T0) the MenC conjugate booster vaccination. Geometric mean number of TT-specific memory B cells per 100,000 B cells.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
30
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.1938 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Tetanus Toxoid IgG memory B cells 10 vs. 15 at T0 | ||||||||||||||||
Statistical analysis description |
Mann-Whitney U test on circulating Tetanus Toxoid specific IgG memory B cells prior to (T0) the MenC conjugate booster vaccination. Geometric mean number of TT-specific memory B cells per 100,000 B cells.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
31
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.0007 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Tetanus Toxoid IgG memory B cells 12 vs. 15 at T0 | ||||||||||||||||
Statistical analysis description |
Mann-Whitney U test on circulating Tetanus Toxoid specific IgG memory B cells prior to (T0) the MenC conjugate booster vaccination. Geometric mean number of TT-specific memory B cells per 100,000 B cells.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
27
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.0865 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Tetanus Toxoid specific IgG memory B-cell responses at T1 | ||||||||||||||||
End point description |
Frequency of circulating Tetanus Toxoid specific IgG memory B cells 1 month (T1) after the MenC conjugate booster vaccination. Geometric mean number of TT memory B cells per 100,000 B cells
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T1
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Tetanus Toxoid IgG memory B cells 10 vs. 12 at T1 | ||||||||||||||||
Statistical analysis description |
Mann-Whitney U test on circulating Tetanus Toxoid specific IgG memory B cells 1 month (T1) after the MenC conjugate booster vaccination. Geometric mean number of TT-specific memory B cells per 100,000 B cells.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
32
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.3141 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Tetanus Toxoid IgG memory B cells 10 vs 15 at T1 | ||||||||||||||||
Statistical analysis description |
Mann-Whitney U test on circulating Tetanus Toxoid specific IgG memory B cells 1 month (T1) after the MenC conjugate booster vaccination. Geometric mean number of TT-specific memory B cells per 100,000 B cells.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
35
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.6656 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Tetanus Toxoid IgG memory B cells 12 vs. 15 at T1 | ||||||||||||||||
Statistical analysis description |
Mann-Whitney U test on circulating Tetanus Toxoid specific IgG memory B cells 1 month (T1) after the MenC conjugate booster vaccination. Geometric mean number of TT-specific memory B cells per 100,000 B cells.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
31
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.1701 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
|
|||||||||||||||||
End point title |
Tetanus Toxoid specific IgG memory B-cell responses at T2 | ||||||||||||||||
End point description |
Frequency of circulating Tetanus Toxoid specific IgG memory B cells 1 year (T2) after the MenC conjugate booster vaccination. Geometric mean number of TT memory B cells per 100,000 B cells
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
T2
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
Tetanus Toxoid IgG memory B cells 10 vs. 12 at T2 | ||||||||||||||||
Statistical analysis description |
Mann-Whitney U test on circulating Tetanus Toxoid specific IgG memory B cells 1 year (T2) after the MenC conjugate booster vaccination. Geometric mean number of TT-specific memory B cells per 100,000 B cells.
|
||||||||||||||||
Comparison groups |
10 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
30
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.5701 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Tetanus Toxoid IgG memory B cells 10 vs. 15 at T2 | ||||||||||||||||
Statistical analysis description |
Mann-Whitney U test on circulating Tetanus Toxoid specific IgG memory B cells 1 year (T2) after the MenC conjugate booster vaccination. Geometric mean number of TT-specific memory B cells per 100,000 B cells.
|
||||||||||||||||
Comparison groups |
10 year olds v 15 year olds
|
||||||||||||||||
Number of subjects included in analysis |
33
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.5507 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Statistical analysis title |
Tetanus Toxoid IgG memory B cells 12 vs. 15 at T2 | ||||||||||||||||
Statistical analysis description |
Mann-Whitney U test on circulating Tetanus Toxoid specific IgG memory B cells 1 year (T2) after the MenC conjugate booster vaccination. Geometric mean number of TT-specific memory B cells per 100,000 B cells.
|
||||||||||||||||
Comparison groups |
15 year olds v 12 year olds
|
||||||||||||||||
Number of subjects included in analysis |
29
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
equivalence | ||||||||||||||||
P-value |
= 0.3566 | ||||||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||||||
Confidence interval |
|||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Adverse events (AEs) are defined as any undesirable experience occurring to a participant during the study, whether or not considered related to the vaccine, the vaccination or the venapuncture.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
There were no SAEs and SUSARs.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
27
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Self reported Adverse event
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
All adverse events reported spontaneously by the participant, his/her parent(s) or observed by the principal investiga¬tor or her staff . | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Frequency threshold for reporting non-serious adverse events: 0.05% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||
Substantial protocol amendments (globally) |
|||
| Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
05 Jun 2014 |
For adequate protection against Meningococcal C (MenC), sufficient circulating antibodies are required. The first results of the TIM study show that all 10-, 12- and 15-year-olds in the study still have more than enough antibodies 1 year after the study vaccination (booster). However, the rate of decline of the circulating antibodies seems to be the least rapid in the 15-year-olds. We want to further monitor the (differences between the age groups in) the rate of decline of MenC-specific antibodies after the study vaccination and therefore are going to take blood and saliva 3 years after the study vaccination. |
||
Interruptions (globally) |
|||
| Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
| Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
| Missing data: * Memory T cells were not measured (all time points) * Memory B cell analysis is missing for T3 * IgA in serum and saliva are missing for T3 | |||
Online references |
|||
| http://www.ncbi.nlm.nih.gov/pubmed/24963638 http://www.ncbi.nlm.nih.gov/pubmed/26100925 http://www.ncbi.nlm.nih.gov/pubmed/26458006 http://www.ncbi.nlm.nih.gov/pubmed/27817957 |
|||